Obsessive-Compulsive Symptom
Conditions
Brief summary
This is a randomized, double-blind, parallel-group, sham-controlled trial that aims to investigate the effectiveness of transcranial direct current stimulation (TDCS) on improving symptoms, quality of life, depression, and cognitive functions in 39 patients with obsessive-compulsive disorder (OCD) that are randomized in 3 experimental groups.
Interventions
DEVICEtranscranial direct current stimulation
Patients will receive 10 sessions of 20 minutes of either 1 mA, 2 mA or sham electrical stimulation on 5 consecutive days
Sponsors
The National Brain Mapping Laboratory (NBML)
Ardabil University of Medical Sciences
Leibniz Research Centre for Working Environment and Human Factors
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Obsessive-compulsive Disorder by a psychiatrist and DSM-5-based behavioral checklist * being 18-50 years old * providing written informed consent * If female, negative urine pregnancy test * stable medication regime especially the classical neuroleptics and all CNS-activating medications, if taken, 4-6 weeks before the experiment and during the experiment
Exclusion criteria
* smoker * pregnancy * alcohol or substance dependence * history of seizure * history of neurological disorder * history of head injury * presence of ferromagnetic objects in the body that are contraindicated for brain stimulation of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Yale-Brown Obsessive-Compulsive (Y-BOCS) rating scale | up to 1 month after the intervention | Score in the Yale-Brown Obsessive-Compulsive (Y-BOCS). Total scores on the measure range from 0 to 40, with a score of 0-7 indicating subclinical symptoms, 8-15 mild symptoms, 16-23 moderate symptoms, 24-31 severe symptoms and 32-40 extreme symptoms. |
| Beck Anxiety Questionnaire (BAI) | up to 1 month after the intervention | Score in the Beck Anxiety Questionnaire (BAI). The BAI scores are classified as minimal anxiety (0 to 7), mild anxiety (8 to 15), moderate anxiety (16 to 25), and severe anxiety (30 to 63). |
| Response inhibition task 1 | up to 1 month after the intervention | Performance in the response inhibition tasks (Flanker test) |
| Working memory task | up to 1 month after the intervention | Performance in the working memory task as an executive function task |
| Response inhibition task 2 | up to 1 month after the intervention | Performance in the response inhibition tasks (Go/No-Go task) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Beck Depression Questionnaire (BDI-II) | up to 1 month after the intervention | Score in the Beck Depression Questionnaire (BDI-II). The BDI-II scores are classified as below: Score of 1-10: These ups and downs are considered normal. Score of 11-16: Mild mood disturbance. Score of 17-20: Borderline clinical depression. Score of 21-30: Moderate depression. Score of 31-40: Severe depression. Score of 40+ Extreme depression. |
| Quality of Life Questionnaire (WHOQUL) | up to 1 month after the intervention | Score in the Quality of Life Questionnaire. It has 26 items and each item is rated on a 5-point scale with a higher score indicative of higher quality of life. |
| electroencephalogram (EEG) oscillatory power | up to 1 month after the intervention | Change in the EEG power in alpha, delta, theta and beta bands |
| electroencephalogram (EEG) functional connectivity | up to 1 month after the intervention | Change in the EEG functional connectivity |
Countries
Iran
Outcome results
None listed